GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C.
Details for the panel discussion are as follows:
| Title: | Muscle Wasting in Weight Loss Therapy |
| Session: | Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues |
| Presenter: | Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
| Date/Time: | Friday, December 6, 2024 at 9:30 am ET |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
[email protected]
This press release was published by a CLEAR® Verified individual.
